BioStock: Sprint Biosciences CSO comments on further VADA validation

After last year’s out-licensing of Vps34, the focus is now on the next program in Sprint Bioscience’s portfolio. The VADA program has come the furthest and new research findings provide further validation to the target protein VRK1. In addition to a better understanding of the role the protein plays in cancer, the results also point to a broadened commercial potential for VADA. BioStock contacted Sprint Bioscience’s Head of Research Martin Andersson to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/sprint-biosciences-cso-comments-on-further-vada-validation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se